Bayer Beats Q1 Earnings Estimates but $7.25 Billion Roundup Settlement and Supreme Court Ruling Dominate the Investment Case

Bayer posted strong Q1 earnings (EPS €2.81) but legal overhangs — Roundup opt-out deadline and Supreme Court preemption case — keep stock under pressure, down 7.85% in May.

Bayer’s first-quarter results surprised on the upside, yet the stock continues to drift lower as two legal deadlines overshadow the operating story. The pharmaceutical and crop science group reported earnings per share of €2.81 on revenue of €13.405 billion, with the troubled Crop Science division proving more resilient than analysts had feared. But investors are focusing elsewhere: an opt-out window for the proposed $7.25 billion Roundup settlement closes on June 4, and the US Supreme Court is expected to rule on a related preemption case by the end of June.

The stock slipped 1.44% to €37.54 on the day the secondary article was written, extending a monthly decline to 7.85%. The shares are now trading below their 50-day moving average, deep in a consolidation phase that has pushed the February year-high further out of reach. Market observers believe the solid operating performance was already priced in, leaving the legal overhang to dictate near-term direction.

That legal burden is heavy on cash. Free cash flow swung to negative €2.3 billion in the first quarter, dragged down by roughly €2.0 billion in outflows related to PCB and glyphosate litigation. Net debt stood at €32.5 billion at the end of March, and the company’s provisions and liabilities for legal disputes jumped from €7.8 billion to €11.8 billion. An €8 billion bank loan facility is providing immediate liquidity support.

Under the tentative settlement, approved by a Missouri judge, claimants who attribute a non-Hodgkin lymphoma diagnosis to long-term glyphosate exposure can accept the deal — which covers both existing and future claims — or opt out by the June deadline and pursue their own lawsuits. That opt-out rate will determine how much of the risk remains. Meanwhile, Bayer has built additional reserves, and the 2026 dividend is expected to be minimal at just €0.11 per share, reflecting the priority given to debt reduction.

The Supreme Court’s decision in Durnell v. Monsanto could prove even more consequential. The case tests whether federal law — specifically the EPA’s determination that glyphosate’s label warnings are adequate — preempts state-law failure-to-warn claims. A ruling in Bayer’s favor would undercut roughly 80% of the remaining Roundup cases. Oral arguments in late April gave no clear signal; several justices appeared sympathetic to the argument that state claims can proceed despite the EPA’s stance.

Operationally, the company is holding up well. EBITDA before special items rose 9% to €4.453 billion, and Bayer confirmed its full-year currency-adjusted guidance, including EBITDA of €9.6 billion to €10.1 billion. CEO Bill Anderson reiterated confidence that the legal cloud can be substantially lifted this year, with or without a favorable Supreme Court ruling.

The next catalyst on the calendar is May 27, when Bayer management presents at the Deutsche Bank European Champions Conference in Frankfurt. Investors will be looking for concrete details on efficiency programs and a credible path to reducing the €32.5 billion debt pile. Should the board deliver a convincing roadmap, the €40 resistance level — previously flagged by chartists — could come back into focus. Until the opt-out deadline and the Supreme Court decision pass, however, the share price is likely to remain hostage to legal headlines rather than operating fundamentals.